Verismo Therapeutics Secures $28 Million for KIR-CAR Advancements in Cancer Treatment
Verismo Therapeutics Secures $28 Million for KIR-CAR Advancements in Cancer Treatment
Verismo Therapeutics, a clinical-stage company at the forefront of innovating CAR T cell therapy, has recently made headlines with its announcement of a significant investment. On April 15, 2026, they shared that HLB Innovation, its parent company, has provided a hefty $28 million aimed at propelling the clinical development of its novel KIR-CAR platform technology. This financial support comes as Verismo prepares for a landmark event: the presentation of their KIR-CAR clinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, scheduled for April 20, 2026.
The funding will specifically bolster ongoing Phase 1 clinical trials for SynKIR™-110 and SynKIR™-310, Verismo's leading product candidates. SynKIR™-110 targets solid tumors expressing mesothelin, while SynKIR™-310 addresses relapsed/refractory B cell non-Hodgkin lymphomas. The STAR-101 trial for SynKIR™-110 (NCT05568680) and CELESTIAL-301 trial for SynKIR™-310 (NCT06544265) are pivotal in the landscape of cellular therapies, especially given the existing challenges faced by traditional CAR T therapies in treating these malignancies.
As part of the AACR event, Verismo will showcase its findings in one of the industry’s most esteemed settings, underscoring the importance of their research. Bryan Kim, the CEO and co-founder of Verismo Therapeutics, emphasized the crucial timing of this investment, stating, “This funding ensures we have the resources to fully capitalize on that momentum — advancing our programs toward the data readouts that will define the potential for multi-chain KIR-CAR cell therapy.”
The initial results from the Phase 1 trial of SynKIR™-110 will be unveiled during the Late-Breaking Clinical Trials plenary session at AACR, marking a notable achievement for both Verismo and the wider oncology research community. Initial results may provide insight concerning the efficacy and safety profile of their KIR-CAR approach as they move towards commercialization.
In addition, Verismo has planned a series of presentations that will discuss the potential advantages of its platform. Notably, a poster presentation scheduled for April 21, 2026, will highlight how SynKIR™-310 has outperformed traditional CD3-based CAR T therapies in preclinical studies, particularly in B cell non-Hodgkin lymphoma models. This could indicate a promising shift for treatments resistant to existing therapies, which often face significant hurdles.
About Verismo Therapeutics' KIR-CAR Platform
The KIR-CAR platform represents a significant evolution in CAR T technology. It employs a multi-chain mechanism that promises higher efficacy against a range of tumors, particularly solid tumors, which have traditionally been difficult to treat with CAR T approaches. The design leverages NK cell-derived killer immunoglobulin-like receptors (KIR) coupled with DAP12, enabling a unique activation pathway independent of the conventional CD3 signaling mechanism that is often a limitation in existing CAR therapies. By circumventing some of these constraints, Verismo’s therapy aims to deliver more durable responses and reduce T cell exhaustion, a common issue that hampers the effectiveness of single-chain CAR T cells.
As Verismo Therapeutics continues to push the boundaries of CAR T cell technology, this latest investment serves as an affirmation of the potential that lies ahead. The oncology community eagerly awaits more information from their upcoming presentations, which could pave the way for novel treatments addressing significant unmet medical needs in cancer therapy.
In conclusion, Verismo Therapeutics’ strategic advancements underscore the promise of KIR-CAR therapy in the battle against cancer. With the support of HLB Innovation and the imminent data presentations at AACR 2026, the company is not just aiming for clinical success but seeks to transform how cancer can be treated. For more updates on their progress, visit Verismo Therapeutics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.